Genomic Health (GHDX) Misses Q4 EPS by 2c, Slight Miss on Revenues; Offers FY18 EPS Mid-Point Guidance Above Consensus, FY18 Revenue Outlook Below Consensus

Note: EPS may not be comparable

Genomic Health (NASDAQ: GHDX) reported Q4 EPS of $0.05, $0.02 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $87.46 million versus the consensus estimate of $88.9 million.

GUIDANCE:

Genomic Health sees FY2018 EPS of $0.32-$0.50, versus the consensus of $0.34. Genomic Health sees FY2018 revenue of $355-382 million, versus the consensus of $383.77 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c